---
document_datetime: 2025-12-10 15:42:47
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aimovig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aimovig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1802525
conversion_datetime: 2025-12-23 06:12:57.660353
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aimovig

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB / EMA/VR/0000309660 | This was an application for a group of variations. | 01/12/2025                          |                                             | SmPC, Annex II, Labelling        |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| and PL   |
|----------|

<div style=\"page-break-after: always\"></div>

|                                       | B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.a Tightening of specification limits - Accepted                                                                                                                                                                                                                                                                                                                                                                            |            |     |                   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type II /                   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final study report for the non-interventional (NIS) study CAMG334A2023; this is a non-interventional study to examine patient characteristics and drug utilization patterns in migraine patients treated with prophylactic drugs in Nordic countries, listed as a category 3 PASS in the RMP. The RMP version 5.0 has also been | 27/11/2025 | N/A | EMA/VR/0000267640 |
| Variation type IB / EMA/VR/0000262285 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where                                                                                                                                                                                                                                      | 05/05/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

| no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted                                      |
| B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                     |
| B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.z Other changes - Accepted                                                     |